Figure 7B reveals that pre-treatment of PPARα-shRNA also notably abrogated the antidepressant-like actions of chiglitazar in the CRS model of depression, as the (CRS + chiglitazar + PPARα-shRNA)-treated mice had evidently more immobility in the FST [ANOVA: F(6, 63) = 21.437, P < 0.01] and TST [ANOVA: F(6, 63) = 24.802, P < 0.01] as well as less sucrose preference [ANOVA: F(6, 63) = 26.949, P < 0.01] than both the (CRS + chiglitazar)-treated and (CRS + chiglitazar + Control-shRNA)-treated mice (n = 10, P < 0.01). This evidence concerns the gene PPARA and depressive symptom measurement.